Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2011.06.043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.
Int J Cancer
September 2023
Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità (ISS), Rome, Italy.
Article Synopsis
- * Combining the drugs romidepsin (HDCAi) and IFN-α2b enhances the effectiveness against melanoma by reducing cell growth and invasiveness, and overcoming resistance to vemurafenib (VEM).
- * The combination therapy not only helps reactivate immune signals but also improves the immune response against VEM-resistant melanoma cells, suggesting a way to enhance treatment strategies for metastatic melanoma patients.
Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma.
EBioMedicine
January 2023
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address:
Background: Whether immunotherapy combined with different histone deacetylases (HDAC) inhibitors in refractory or relapsed natural killer/T-cell lymphoma (NKTCL) is superior to each agent is still lacking in head-to-head clinical trials or preclinical evidence.
Methods: NKTCL cell line xenograft models (CDX) in immunocompetent, human programmed cell death protein 1 (PD1) knock-in genetically engineered mice were used to investigate the combination effects. Different types and dosages of HDAC inhibitors were investigated.
Strategies to Optimize Adherence in Patients with Mycosis Fungoides.
Cells
December 2021
Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
Patient adherence to medications for common skin conditions has been extensively studied over the past two decades, and suboptimal adherence is a primary contributor to treatment failure. The impact of sub-par adherence in cutaneous T-cell lymphoma (CTCL) patients has been largely unexplored, and promoting adherence in this patient population may represent a promising area of consideration for improving treatment outcomes. We apply patient adherence strategies that have been studied in dermatology to CTCL and provide concrete examples of how these strategies can be used to improve adherence in the CTCL setting.
View Article and Find Full Text PDFThe synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1.
Blood Adv
October 2020
Cutaneous Lymphoma Program, Department of Dermatology, University of Pittsburgh, Pittsburgh, PA; and.
The therapy of advanced mycosis fungoides (MF) presents a therapeutic challenge, and the search for new therapeutic targets is ongoing. Poly(ADP-ribose) polymerase 1 was shown to be upregulated in patients with advanced MF and could be druggable by a new class of chemotherapeutic agents, PARP-1 inhibitors, which are already in clinical trials for other malignancies; however, the role of PARP-1 inhibitors in MF has never been established. We examined the efficacy of talazoparib in the murine model of cutaneous T-cell lymphoma.
View Article and Find Full Text PDFiNOS/NO is required for IRF1 activation in response to liver ischemia-reperfusion in mice.
Mol Med
June 2020
Thomas E. Starzl Transplant Institute, Department of Surgery, University of Pittsburgh, 3471 Fifth Avenue, Kaufmann Medical Building, Suite 300, Pittsburgh, PA, 15213, USA.
Background: Ischemia and reperfusion (I/R) induces cytokines, and up-regulates inducible nitric oxide synthase (iNOS), interferon regulatory factor-1(IRF1) and p53 up-regulated modulator of apoptosis (PUMA), which contribute to cell death and tissue injury. However, the mechanisms that I/R induces IRF1-PUMA through iNOS/NO is still unknown.
Methods: Ischemia was induced by occluding structures in the portal triad (hepatic artery, portal vein, and bile duct) to the left and median liver lobes for 60 min, and reperfusion was initiated by removal of the clamp.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!